The vaccine-makers fighting COVID-19 garnered significant popularity and profits over the past two years. However, with the global pandemic receding, the industry is facing headwinds from recession risks. Access to capital has also become seemingly more difficult than in 2021.
On top of it, research and development, which is vital for the biotech industry, is an expensive and lengthy process. Also, the firms face litigation risks.
